Abbott and Tandem Diabetes Care recently announced the wireless integration of Abbott’s FreeStyle Libre 2 Plus continuous glucose monitor with the Tandem t:slim X2 insulin pump in the US.
Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs. $2.5 billion in 2022, with just under 70% stemming from the US, according to a report from Bloomberg Intelligence.
Protein drugs are notoriously difficult to deliver orally – but scientists have developed a new type of oral capsule that could deliver insulin and other similar drugs.
The South Korean company is set to create a new facility in West Virginia to house insulin manufacturing and to deliver its insulin products in the country.
Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate....
Sernova and Evotec are teaming up on an implantable beta cell replacement therapy to replace insulin injections for the millions of patients with diabetes.
Novo Nordisk is expanding its existing collaborative research partnership in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).
Takara Bio Europe has announced a licensing agreement with Denmark’s PanCryos, a pre-clinical stage biotech company, for its clinical-grade human embryonic stem (hES) cell lines, starting material for cell therapy development.
This month marks a major US milestone for biosimilar medicines as five years ago, September 2015, saw the first biosimilar made available to US patients – the Sandoz developed Zarxio (filgrastim-sndz).
Abbott’s glucose sensing technology and a tubeless insulin delivery system developed by Insulet are set to create a personalized diabetes management solution.
Through funding by Novo Nordisk and the NIH, researchers from MIT have come up with a microneedle containing capsule able to release drug substance into the bloodstream.
Asia’s largest integrated insulins facility, operated by a subsidiary of Biocon in Malaysia, receives GMP compliance certification from Ireland’s HPRA.
The US market for insulin biosimilars is set to open up in 2020, and the head of biopharmaceuticals at Sandoz explained why he is confident of an ‘acceleration’ of the US biosimilar market in the coming years.
French technology firm Cellnovo has selected Flex Ltd to build a production line in Romania, to manufacture insulin cartridges for its diabetes management system.
The US FDA has approved Basaglar, a ‘follow-on’ version of Sanofi’s long-acting insulin Lantus developed in a joint venture between Eli Lilly and Boehringer Ingelheim.
Dutch scientists have 3D printed a protective scaffold that could make cell transplant-based diabetes treatment more successful and eliminate the need for immunosupressive drugs.
Orgenesis has partnered ATMI and established a subsidiary in Belgium in order to manufacture cells for clinical trials of its insulin-producing regenerative drug.
The FDA has issued Eli Lilly with a warning letter detailing a significant deviation from cGMP at its API production facility in Puerto Rico, which makes ingredients used in Humalog (insulin lispro), a diabetes treatment.
Access Pharmaceuticals’ insulin diabetes treatment has shown promise in preclinical trials, achieving over 80 per cent oral bioavailability, leading the company to target proof-of-concept studies in humans.
